A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

New England Journal of Medicine

Volumn 350, Issue 11, 2004, Pages 1081-1092

  Coombes, R Charles ^a,v   Hall, Emma ^b   Gibson, Lorna J ^a   Paridaens, Robert ⁱ   Jassem, Jacek ^j   Delozier, Thierry ^k   Jones, Stephen E ^l   Alvarez, Isabel ^m   Bertelli, Gianfilippo ^c   Ortmann, Olaf ⁿ   Coates, Alan S ^o   Bajetta, Emilio ^p   Dodwell, David ^d   Coleman, Robert E ^e   Fallowfield, Lesley J ^f   Mickiewicz, Elizabeth ^q   Andersen, Jorn ^r   Lønning, Per E ^s   Cocconi, Giorgio ^t   Stewart, Alan ^g   Stuart, Nick ^h   Snowdon, Claire F ^a   Carpentieri, Marina ^u   Massimini, Giorgio ^u   Bliss, Judith M ^b   more..

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c South West Wales Cancer Institute ^*  (United Kingdom)

^d Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h YSBYTY GWYNEDD   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k CENTRE FRANÇOIS BACLESSE   (France)

^l Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^m HOSPITAL DONOSTIA   (Spain)

ⁿ UNIVERSITY OF REGENSBURG   (Germany)

^o UNIVERSITY OF SYDNEY   (Australia)

^p NATIONAL CANCER INSTITUTE   (Italy)

^q Instituto Angel Roffo   (Argentina)

^r AARHUS UNIVERSITY HOSPITAL   (Denmark)

^s UNIVERSITY OF BERGEN   (Norway)

^t UNIVERSITY HOSPITAL OF PARMA   (Italy)

^u PFIZER INC   (United States)

^v HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE; ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN;

ABDOMINAL CRAMP; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MELANOMA; MORTALITY; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; NEOPLASM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PAIN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL; SWEATING; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 10744223655     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040331     Document Type: Article

References (42)

1. Beatson GT. On the new treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-7.
2. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980-9.
3. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of IC46474. Br J Cancer 1971;25:270-5.
4. Jordan VC. Third annual William L. McGuire Memorial Lecture: "studies on the estrogen receptor in breast cancer" - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995;36:267-85.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
6. Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst 1996;88:1791-3.
7. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumors. J Natl Cancer Inst 1996;88: 1529-42.
8. Goldhirsh A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
9. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
10. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-52. [Erratum, Cancer 1999; 85:1010.]
11. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-52. [Erratum, Cancer 1999; 85:1010.]
12. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
13. Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52:5933-9.
14. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988;30:391-4.
15. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999;10:377-84.
16. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
17. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.
18. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-8.
19. Goldstein SR. The effect of SERMS on the endometrium. Ann N Y Acad Sci 2001; 949:237-42.
20. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
21. Cox DR. Regression models and lifetables. J R Stat Soc [B] 1972;34:187-220.
22. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
23. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:71-85.
24. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-9. [Erratum, J Natl Cancer Inst 1997;89:590.]
25. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-9. [Erratum, J Natl Cancer Inst 1997;89:590.]
26. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-9.
27. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359: 2131-9. [Erratum, Lancet 2002;360:1520.]
28. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359: 2131-9. [Erratum, Lancet 2002;360:1520.]
29. Boccardo F, Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001;119:4209-15.
30. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82:Suppl 1:S6. abstract.
31. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002;21:4921-31.
32. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
33. Dowsett M. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82: Suppl 1:S7. abstract.
34. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
35. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361: 296-300.
36. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
37. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-51.
38. Bajetta E, Martinetti A, Zilembo N, et al. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol 2002;13:1059-66.
39. Harper-Wynne C, Koss G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614-21.
40. Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia. J Clin Oncol 2001;19:2767.
41. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-32.
42. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients.' Ann Oncol 2004;15:211-7.